ZYDUS LIFESCIENCES LIMITED

DelveInsight's 'Rosacea Pipeline Insight, 2024' report highlights 25+ key companies developing 25+ pipeline drugs for Rosacea, with therapies in various stages of clinical development. Key companies include Sol-Gel Technologies, Maruho Co., Ltd., AOBiome LLC, and others. Emerging therapies like Epsolay, M 1220, and BMX-010 are expected to impact the market. Regulatory approvals and collaborations are noted, such as Sol-Gel Technologies' agreement with Searchlight Pharma Inc. and Zydus Lifesciences' FDA approval for Metronidazole Topical cream.

Keytruda, a cancer drug, achieved $25 billion in global sales, treating 40 cancers in the US and 17 in India. Its mechanism activates the immune system to fight cancer cells, categorized as immunotherapy. Despite high costs, it has shown remarkable results in some cases, prompting Indian drugmakers to develop affordable biosimilars as patents expire.

Trastuzumab biosimilars market to grow from $4.27B in 2023 to $5.43B in 2024, reaching $14.69B by 2028, driven by market expansion, patent expirations, and competitive pricing.

Zydus Lifesciences receives USFDA approval for Fludrocortisone Acetate Tablets USP, 0.1 mg, to be manufactured at Moraiya, Ahmedabad. Indicated for adrenocortical insufficiency and adrenogenital syndrome, the tablets had USD 19.9 mn annual sales in the US.

Zydus Lifesciences received FDA approval for Fludrocortisone Acetate tablets, partnered with CSIR-CDRI for osteoporosis treatment, and signed a pact with Viwit Pharmaceuticals for MRI injectables. Shares rose 0.14% to Rs 1,021.50 on NSE.

ICMR partners with Zydus Lifesciences for Phase 2 trials of Desidustat, a HIF-prolyl hydroxylase inhibitor, to treat sickle cell disease. The double-blind, randomized, placebo-controlled study aims to assess efficacy and safety, following DCGI approval.

Zydus Lifesciences and ICMR initiate Phase 2 clinical trials of Desidustat for Sickle Cell Disease, aiming to evaluate efficacy and safety in a double-blind, randomized, placebo-controlled study.

The global peptide therapeutics market is projected to grow from $42.1B in 2023 to $56.2B by 2030, driven by technological advancements, increasing demand for targeted treatments, and the rising incidence of chronic diseases. Peptide therapeutics offer high specificity and low toxicity, making them attractive for treating conditions like cancer and diabetes. Innovations in peptide engineering and delivery systems are enhancing their efficacy and stability, expanding their therapeutic potential across various diseases.

ICMR formalizes MoA with Zydus Lifesciences for phase-2 trials of Desidustat in sickle cell disease patients, aiming to develop innovative, affordable healthcare solutions. Desidustat, invented in India, addresses limitations of current treatments like Hydroxyurea and blood transfusions. The study, co-funded by ICMR, will evaluate Desidustat's efficacy and safety.

Zydus Lifesciences receives USFDA approval for Paliperidone ER Tablets (1.5 mg, 3 mg, 6 mg, 9 mg), indicated for schizophrenia and schizoaffective disorder treatment, to be manufactured at SEZ, Ahmedabad. Annual U.S. sales for the drug were $47.1 million (IQVIA MAT July 2024).